myelodysplastic

Celgene Corp.'s Vidaza—for bone-marrow disorders called myelodysplastic syndromes

New Lapses at J&J's Doxil Supplier Peter Loftus 2011

Revlimid was approved in December 2005 to treat a bone-marrow disorder known as myelodysplastic syndromes and later approved for multiple myeloma, a type of blood cancer.

FDA Says Celgene Drug 2008

The drug is currently approved in the U.S. to treat another type of blood cancer called myelodysplastic syndrome, or MDS.

Celgene's Revlimid Could See European Pricing Upside: Report 2006

The longtime hospital pharmacist, now 57, was soon diagnosed with a precancerous blood disease called myelodysplastic syndrome.

The Seattle Times 2010

In 2008 acquired Pharmion, developer of demethylating agent Vidaza, approved in 2004 to treat blood disorders called myelodysplastic syndromes.

News from The Scientist Alla Katsnelson 2010

In 2008 acquired Pharmion, developer of demethylating agent Vidaza, approved in 2004 to treat blood disorders called myelodysplastic syndromes.

News from The Scientist Alla Katsnelson 2010

Fourteen months of chemotherapy killed 96 percent of the bone cancer, but it killed her ability to make new blood cells, a condition called myelodysplastic syndrome or "preleukemia."

STLtoday.com Top News Headlines 2009

"What we know is that it's a 7-year-old in Italy, who has something called myelodysplastic syndrome," she said.

TheBostonChannel.com - News 2008

Ms. Price is now in the hospital following her bone marrow transplant to treat myelodysplastic syndrome, a form of cancer that occurs when blood-forming cells in the bone marrow are damaged.

A Financial Incentive for Better Bedside Manner Laura Landro 2011

Patients receiving transplants suffer from hematological or non-hematological malignancies, myelodysplastic syndromes, hematological congenital disorders, aplastic anemia, inborn errors of metabolism, or congenital immunodeficiencies.

Stem Cell Lab 2010